AXSM - Company ID 0001579428
The table below shows Axsome Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $191.20M | $170.99M | $150.04M | $121.46M | $104.76M | $87.17M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $52.68M | $40.16M | $49.54M | $44.78M | $45.39M | $49.85M |
Axsome Therapeutics, Inc. reported annual revenue of $638.50M for fiscal year 2025. That is up 65.5% from $385.69M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $185.00M |
| $150.24M |
| $130.28M |
| $120.79M |
| $95.56M |
| $103.55M |
| Operating income | -$63.36M | -$46.11M | -$36.71M | -$56.98M | -$62.62M | -$78.05M |
| Income tax | $0.00 | $0.00 | -$960.00K | $0.00 | $0.00 | $0.00 |
| Net income | -$64.54M | -$47.23M | -$47.97M | -$59.41M | -$64.60M | -$79.34M |
| EPS (diluted) | -$1.26 | -$0.94 | -$0.97 | -$1.22 | -$1.34 | -$1.67 |